Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
san diego blog main
san diego top stories
5
×
boston blog main
boston top stories
fda
national top stories
new york blog main
new york top stories
biotech
san francisco blog main
san francisco top stories
akcea therapeutics
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
drugs
indiana blog main
indiana top stories
inotersen
national
patisiran
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
rna interference
seattle blog main
seattle top stories
tafamidis
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
ambys medicines
amicus therapeutics
ampio pharmaceuticals
What
fda
5
×
patients
5
×
drug
ago
alnylam
disease
medicine
time
add
akcea
amyloidosis
approve
approved
aren’t
attr
available
awaits
battle
bio
biological
called
cancer
carbidopa
combination
control
crossed
daily
debilitating
decades
decision
developers
discovered
drugs
eisai
experience
fingers
flags
friday
gene
genetic
Language
unset
Current search:
patients
×
fda
×
" san diego top stories "
×
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision